Skip to main content
Toggle navigation
Menu
Overall search
Search ClinicalINFO
In affiliation with
HIV.gov
Search
Close
Main navigation
Home
About
Guidelines
Drug Database
Glossary
News
Resources
Contact Us
English
Toggle Dropdown
English
Español (Spanish)
Home
Search Results
Overall search
Search ClinicalINFO
Search Results
661 – 680
of
3979
Tomar fármacos contra el VIH antes de la exposición podría ayudar a prevenir la infección
https://clinicalinfo.hiv.gov/node/11103
Las personas con VIH tienen mayores probabilidades de muerte súbita cardiaca
https://clinicalinfo.hiv.gov/node/11104
VHC aumenta riesgo de pacientes con sida de muerte prematura
https://clinicalinfo.hiv.gov/node/11105
El VIH aumenta el riesgo de cáncer pulmonar, más allá del tabaquismo
https://clinicalinfo.hiv.gov/node/11106
La 'carga viral' del compañero es un factor importante en la transmisión del VIH, según un estudio
https://clinicalinfo.hiv.gov/node/11108
Boletín de Tratamientos Experimentales Contra el SIDA - BETA
https://clinicalinfo.hiv.gov/node/11109
PI Perspective en Español
https://clinicalinfo.hiv.gov/node/11110
Wise Words en Español
https://clinicalinfo.hiv.gov/node/11111
Efavirenz / Lamivudine / Tenofovir Disoproxil Fumarate
https://clinicalinfo.hiv.gov/drugs/efavirenz-lamivudine-tenofovir-disoproxil-fumarate/symfi-lo-fda-label
Page 404
https://clinicalinfo.hiv.gov/page-404
Página 404
https://clinicalinfo.hiv.gov/page-404
Guidelines Archive
https://clinicalinfo.hiv.gov/guidelines-archive
Statement—NIH Study Finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women
https://clinicalinfo.hiv.gov/news/statement-nih-study-finds-long-acting-injectable-drug-prevents-hiv-acquisition-cisgender-women
Table 3. Laboratory Testing Schedule for Monitoring People with HIV Before and After Initiation of Antiretroviral Therapy
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/tests-initial-assessment-and-follow-full
Table 20. Common and/or Severe Adverse Effects Associated with Antiretroviral Therapy
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adverse-effects-antiretroviral-agents-full
Appendix B, Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-nrti-full
Table 18. Concomitant Use of Selected Antiretroviral Drugs and Hepatitis C Virus Direct-Acting Antiviral Drugs for Treatment of Hepatitis C Virus in Adults With HIV
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-hepatitis-c-virus-hcv-full
Appendix B, Table 5. Characteristics of Protease Inhibitors
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-pi-full
Table 2. Treatment of HIV-Associated Opportunistic Infections (Includes Recommendations for Acute Treatment and Secondary Prophylaxis/Chronic Suppressive/Maintenance Therapy)
https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/treatment-hiv-associated-full
Potential Clinically Relevant Interactions between Antimalarial and Antiretroviral Drugs*
https://clinicalinfo.hiv.gov/table/potential-clinically-relevant-interactions-between-antimalarial-and-antiretroviral-drugs
Pagination
First page
«
Previous page
‹
…
Page
30
Page
31
Page
32
Page
33
Current page
34
Page
35
Page
36
Page
37
Page
38
…
Next page
›
Last page
»